To confirm the safety of the Gastrointestinal hormone Ghrelin against chronic kidney disease patients

JRCT ID: jRCTs031180354

Registered date:18/03/2019

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: Chronic Kidney Disease
• Date of first enrollment: 16/12/2015
• Target sample size: 6
• Study type: Interventional
• Intervention(s): Drug injection

Outcome(s)

• Primary Outcome: Time course of the blood concentration of Ghrelin
• Secondary Outcome: Percentage of the appearance of the side effects of Ghrelin

Key inclusion & exclusion criteria

• Age minimum: 20 years old
• Age maximum: not applicable
• Gender: Both

Include criteria

Age 20 and up
Stage G4 and G5 Chronic Kidney Disease Patient of Keio University Hospital outpatient clinic who have not underwent dialysis
BMI lower than 25
Who have agreed to cooperate with this clinical study with an excellent understanding

Exclude criteria

Who have severe liver dysfunction
Who have cancer
Who have severe infectious disease
Who have mental disorders
Who have allergy against wheat, eggs and milk
Women with a possibility of pregnancy
Who have been decided to be excluded by the primary doctor

Related Information

• Primary Sponsor: Itoh Hiroshi